دانلود کتاب وضعیت حاد بالینی در بیماری کبد چرب غیر الکلی
Clinical Dilemmas in Non-Alcoholic Fatty Liver Disease, 1ed

About the Author

Contents

Chapter 1 Non-alcoholic fatty fiver disease: Hype or harm?
Chapter 2 NAFLD: A worldwide problem
Chapter 3 Is insulin resistance the principal cause of NAFLD?
Chapter 4 Paediatric NAFLD: A distinct disease with the propensity for progressive fibrosis
Chapter 5 Non-alcoholic fatty liver disease (NAFLD) as cause of cryptogenic cirrhosis
Chapter 6 Is NAFLD different in absence of metabolic syndrome?
Chapter 7 Occurrence of noncirrhotic HCC in NAFLD
Chapter 8 Fibrosis progression: Putative mechanisms and molecular pathways
Chapter 9 When is it NAFLD and when is it ALD?: Can the histologic evaluation of a liver biopsy guide the clinical evaluation?
Chapter 10 Of men and microbes: Role of the intestinal microbiome in non-alcoholic fatty liver disease
Chapter 11 Can genetic influence in non-alcoholic fatty liver disease be ignored?
Chapter 12 Is there a mechanistic link between hepatic steatosis and cardiac rather than liver events?
Chapter 13 How to best diagnose NAFLD/NASH?
Chapter 14 The clinical utility of noninvasive blood tests and elastography
Chapter 15 Are the guidelines— AASLD, IASL, EASL, and BSG— of help in the management of patients with NAFLD?
Chapter 16 Imaging methods for screening of hepatic steatosis
Chapter 17 Are the advantages of obtaining a liver biopsy outweighed by the disadvantages?
Chapter 18 Screening for NAFLD in high-risk populations
Chapter 19 Defining the role of metabolic physician
Chapter 20 Should physicians be prescribing or patients self-medicating with orlistat, vitamin E, vitamin D, insulin sensitizers, pentoxifylline, or coffee?
Chapter 21 Effects of treatment of NAFLD on the metabolic syndrome
Chapter 22 What are the dangers as well as the true benefits of bariatric surgery?
Chapter 23 Liver transplantation: What can it offer?
Chapter 24 Molecular antagonists, leptin or other hormones in supplementing environmental factors’
Chapter 25 What is the role of antifibrotic therapies in the current and future management of NAFLD?
Chapter 26 Developmental programming of non-alcoholic fatty liver disease